Higher Adherence to the Mediterranean Diet Is Associated with a Lower Risk of Steatotic, Alcohol-Related, and Metabolic Dysfunction-Associated Steatotic Liver Disease: A Retrospective Analysis

被引:1
|
作者
Lee, Ji Yae [1 ]
Kim, Sue [2 ]
Lee, Yaeji [3 ]
Kwon, Yu-Jin [4 ]
Lee, Ji-Won [1 ,5 ]
机构
[1] Yonsei Univ, Severance Hosp, Coll Med, Dept Family Med, Seoul 03722, South Korea
[2] Yonsei Univ Hlth Syst, Severance Hosp, Int Hlth Care Ctr, Seoul 03722, South Korea
[3] Yonsei Univ, Dept Biostat & Comp, Seoul 03722, South Korea
[4] Yonsei Univ, Yongin Severance Hosp, Coll Med, Dept Family Med, Yongin 16995, South Korea
[5] Yonsei Univ, Severance Hosp, Dept Family Med, Coll Med,Inst Innovat Digital Healthcare, Yonsei Ro 50-1, Seoul 03722, South Korea
基金
新加坡国家研究基金会;
关键词
Mediterranean diet adherence; steatotic liver disease; metabolic dysfunction-associated steatotic liver disease; alcohol-related liver disease; CARDIOVASCULAR-DISEASE; HEPATIC STEATOSIS; GUIDELINE; BENEFITS; NOMENCLATURE; NUTRITION; HEALTH;
D O I
10.3390/nu16203551
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Background and Aims: Metabolic liver disease is associated with obesity, insulin resistance, cardiovascular disease, and metabolic disorders. A Mediterranean diet (MD), known for its anti-inflammatory and antioxidant properties, is effective in managing various chronic diseases, including liver diseases. This study aimed to explore the influence of adherence to the MD on the risk of chronic metabolic diseases, including steatotic liver disease (SLD), metabolic dysfunction-associated steatotic liver disease (MASLD), and alcohol-related liver diseases (ALDs). Methods: This retrospective cohort study analyzed 5395 individuals from a single center between 2020 and 2022, grouped by adherence to the MD using the Korean Mediterranean Diet Adherence Score (K-MEDAS). MASLD score, ALD, and cardiovascular risk factors were also assessed. Statistical analyses were performed using 1:1 exact matching and multiple regression to compare the less adherent (K-MEDAS 0-7) and highly adherent (K-MEDAS 8-13) groups. Results: Adjusting for confounding variables, high adherence to the MD was significantly associated with lower rates of SLD (odds ratio [OR] 0.818, 95% confidence interval [CI] 0.700-0.957, p = 0.012), MASLD (OR 0.839, 95% CI 0.714-0.986, p = 0.033), and ALD (OR 0.677, 95% CI 0.671-0.683, p < 0.001). Post-propensity score matching analysis revealed that the highly adherent group exhibited significantly lower triglyceride levels, triglyceride and glucose index, atherogenic Index of Plasma, and Framingham risk scores than the less adherent group. Conclusions: Good adherence to the MD considerably reduces the risk of SLD, MASLD, and ALD, underscoring its protective effects and potential to prevent metabolic liver diseases and their complications.
引用
收藏
页数:11
相关论文
共 50 条
  • [21] GASTROINTESTINAL MALIGNANCY RISK IN METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE
    Nwankwo, Chizoba N.
    Eun, Yong
    Nwankwo, Obinna T.
    Osman, Mohamed K.
    Culpepper-Morgan, Joan A.
    GASTROENTEROLOGY, 2024, 166 (05) : S1474 - S1474
  • [22] Prevalence and Risk Factors of Metabolic Dysfunction-associated Steatotic Liver Disease
    Plaza-Aulestia, Nahia
    Ibarguengoitia-Barrena, Oihane
    Sampedro-Andrada, Blanca
    Juan-Lopez, Cristina San
    Morillo-Montanes, Victoria
    Urionaguena, Irati
    Calvo, Itziar
    Seisdedos, David Montero
    Vega-Alvarez, Lucia
    Llorente, Jose Francisco Garcia
    Revenga, Nuria Vegas
    ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 4669 - 4671
  • [23] Machine learning models and AI in predicting diagnosis and prognosis in alcohol-related and metabolic dysfunction-associated steatotic liver disease
    Roy, Akash
    Verma, Nipun
    METABOLISM AND TARGET ORGAN DAMAGE, 2025, 5 (01):
  • [24] Liver Cancer Risk Across Metabolic Dysfunction-Associated Steatotic Liver Disease and/or Alcohol: A Nationwide Study
    Yun, Byungyoon
    Park, Heejoo
    Ahn, Sang Hoon
    Oh, Juyeon
    Kim, Beom Kyung
    Yoon, Jin-Ha
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2025, 120 (02): : 410 - 419
  • [25] TOLL- LIKE RECEPTOR LIGANDS PATTERN IN ALCOHOL-RELATED LIVER DISEASE AND METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE PATIENTS
    Staltner, Raphaela
    Staufer, Katharina
    Trauner, Michael
    Mueller, Sebastian
    Bergheim, Ina
    HEPATOLOGY, 2024, 80 : S75 - S76
  • [26] Psychosocial risks in metabolic dysfunction-associated steatotic liver disease
    Astrom, Hanne
    Takami Lageborn, Christine
    Hagstrom, Hannes
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2025, 19 (03) : 273 - 290
  • [27] Role of Glucocorticoids in Metabolic Dysfunction-Associated Steatotic Liver Disease
    Polyzos, Stergios A.
    Targher, Giovanni
    CURRENT OBESITY REPORTS, 2024, 13 (02) : 242 - 255
  • [28] Implications of the new nomenclature of steatotic liver disease and definition of metabolic dysfunction-associated steatotic liver disease
    Loomba, Rohit
    Wong, Vincent Wai-Sun
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2024, 59 (02) : 150 - 156
  • [29] Postbiotic supplementation for metabolic dysfunction-associated steatotic liver disease
    Savytska, Maryana
    Baka, Olena
    Manzhalii, Elina
    Kyriienko, Dmytro
    Falalyeyeva, Tetyana
    Zhayvoronok, Maksym
    Kovalchuk, Oleksandr
    Deresh, Nataliya
    Grygoriev, Fedir
    Kobyliak, Nazarii
    JOURNAL OF HEPATOLOGY, 2024, 80 : S610 - S611
  • [30] Advances in research on metabolic dysfunction-associated steatotic liver disease
    Wang, Jiawang
    Wang, Zhongyu
    Yu, Yao
    Cheng, Si
    Wu, Jianping
    LIFE SCIENCES, 2025, 362